Analysts at StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
MediciNova Stock Performance
MNOV stock opened at $1.29 on Monday. The firm has a market capitalization of $63.27 million, a PE ratio of -7.59 and a beta of 0.75. MediciNova has a 1-year low of $1.26 and a 1-year high of $2.66. The business’s 50 day simple moving average is $1.40 and its 200 day simple moving average is $1.56.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. As a group, sell-side analysts predict that MediciNova will post -0.23 EPS for the current fiscal year.
Institutional Trading of MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Read More
- Five stocks we like better than MediciNova
- ETF Screener: Uses and Step-by-Step Guide
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Hilton Demonstrates Asset Light is Right for Investors
- Best Aerospace Stocks Investing
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
